Literature DB >> 20496142

Advanced ampullary carcinoma showing complete response to S-1: report of a case.

Nobutsugu Abe1, Masanori Sugiyama, Hideaki Mizuno, Yutaka Suzuki, Tadahiko Masaki, Toshiyuki Mori, Yutaka Atomi.   

Abstract

We report a case of advanced ampullary carcinoma with para-aortic lymph node metastasis, which showed a complete response to S-1. The patient underwent cholecystectomy and Roux-en-Y choledochojejunostomy, and was then given S-1 orally 80 mg daily for 14 days, followed by 7 days of rest. After four cycles of the S-1 chemotherapy, both the tumor and the swollen paraaortic lymph node had completely disappeared. An additional six cycles were given at the request of the patient. No adverse effects were seen during the S-1 chemotherapy, and the patient has been free of the disease for the 27 months since its completion. Thus, S-1 monotherapy may be considered as a chemotherapeutic strategy for unresectable ampullary carcinoma, although large-scale studies will be required to confirm its true efficacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20496142     DOI: 10.1007/s00595-008-4091-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  An early phase II study of S-1 in patients with metastatic pancreatic cancer.

Authors:  Hideki Ueno; Takuji Okusaka; Masafumi Ikeda; Yoriko Takezako; Chigusa Morizane
Journal:  Oncology       Date:  2005-07-04       Impact factor: 2.935

2.  Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.

Authors:  Takuji Okusaka; Hiroshi Ishii; Akihiro Funakoshi; Kenji Yamao; Shinichi Ohkawa; Soh Saito; Hiroshi Saito; Toshio Tsuyuguchi
Journal:  Cancer Chemother Pharmacol       Date:  2005-09-02       Impact factor: 3.333

3.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.

Authors:  C J Yeo; J L Cameron; T A Sohn; K D Lillemoe; H A Pitt; M A Talamini; R H Hruban; S E Ord; P K Sauter; J Coleman; M L Zahurak; L B Grochow; R A Abrams
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

4.  Gastric small cell carcinoma successfully treated by surgery and postoperative chemotherapy consisting of cisplatin and S-1: report of a case.

Authors:  Naohiko Koide; Akira Suzuki; Hiroyasu Saito; Toshiyuki Sato; Maki Murakami; Hiroyoshi Ota; Shinichi Miyagawa
Journal:  Surg Today       Date:  2007-10-25       Impact factor: 2.549

5.  S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.

Authors:  Junji Furuse; Takuji Okusaka; Narikazu Boku; Shinichi Ohkawa; Akira Sawaki; Toshikazu Masumoto; Akihiro Funakoshi
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-23       Impact factor: 3.333

6.  A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas.

Authors:  Ming-Hsien Lin; Jen-Shi Chen; Helen H-W Chen; Wu-Chou Su
Journal:  Chemotherapy       Date:  2003-06       Impact factor: 2.544

7.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

8.  Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.

Authors:  Rachel P Riechelmann; Carol A Townsley; Sheray N Chin; Gregory R Pond; Jennifer J Knox
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

9.  Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.

Authors:  H Shinchi; K Maemura; H Noma; Y Mataki; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

10.  Phase II study of S-1 in patients with advanced biliary tract cancer.

Authors:  H Ueno; T Okusaka; M Ikeda; Y Takezako; C Morizane
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.